{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:35:17Z","timestamp":1774953317948,"version":"3.50.1"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immunotherapy, by enhancing the endogenous anti-tumor immune responses, is showing promising results for the treatment of numerous cancers refractory to conventional therapies. However, its effectiveness for advanced castration-resistant prostate cancer remains unsatisfactory and new therapeutic strategies need to be developed. To this end, systems pharmacology modeling provides a quantitative framework to test<jats:italic>in silico<\/jats:italic>the efficacy of new treatments and combination therapies. In this paper we present a new Quantitative Systems Pharmacology (QSP) model of prostate cancer immunotherapy, calibrated using data from pre-clinical experiments in prostate cancer mouse models. We developed the model by using Ordinary Differential Equations (ODEs) describing the tumor, key components of the immune system, and seven treatments. Numerous combination therapies were evaluated considering both the degree of tumor inhibition and the predicted synergistic effects, integrated into a decision tree. Our simulations predicted cancer vaccine combined with immune checkpoint blockade as the most effective dual-drug combination immunotherapy for subjects treated with androgen-deprivation therapy that developed resistance. Overall, the model presented here serves as a computational framework to support drug development, by generating hypotheses that can be tested experimentally in pre-clinical models.<\/jats:p>","DOI":"10.1038\/s41598-020-65590-0","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T15:01:45Z","timestamp":1591196505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["A QSP model of prostate cancer immunotherapy to identify effective combination therapies"],"prefix":"10.1038","volume":"10","author":[{"given":"Roberta","family":"Coletti","sequence":"first","affiliation":[]},{"given":"Lorena","family":"Leonardelli","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3671-5353","authenticated-orcid":false,"given":"Silvia","family":"Parolo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9043-7705","authenticated-orcid":false,"given":"Luca","family":"Marchetti","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"key":"65590_CR1","doi-asserted-by":"crossref","unstructured":"Murray, J. D. Mathematical Biology (Springer Berlin Heidelberg, 1989).","DOI":"10.1007\/978-3-662-08539-4"},{"key":"65590_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1142\/S0218202508002796","volume":"18","author":"N Bellomo","year":"2008","unstructured":"Bellomo, N., Li, N. K. & Maini, P. K. On the foundations of cancer modelling: selected topics, speculations and perspectives. Math. Model. Methods Appl. Sci. 18, 593\u2013646, https:\/\/doi.org\/10.1142\/S0218202508002796 (2008).","journal-title":"Math. Model. Methods Appl. Sci."},{"key":"65590_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11538-010-9526-3","volume":"73","author":"R Eftimie","year":"2011","unstructured":"Eftimie, R., Bramson, J. L. & Earn, D. J. D. Interactions Between the Immune System and Cancer: A Brief Review of Non-spatial Mathematical Models. Bull. Math. Biol. 73, 2\u201332, https:\/\/doi.org\/10.1007\/s11538-010-9526-3 (2011).","journal-title":"Bull. Math. Biol."},{"key":"65590_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-03759-2_1","volume-title":"Managing Complexity, Reducing Perplexity","author":"Thomas Hillen","year":"2014","unstructured":"Hillen, T. & Lewis, M. A. Mathematical Ecology of Cancer. In Delitala, M. & Ajmone Marsan, G. (eds) Managing Complexity, Reducing Perplexity., 1\u201313, https:\/\/doi.org\/10.1007\/978-3-319-03759-2_1 (Springer International Publishing, Cham, 2014)."},{"key":"65590_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41598-017-00854-w","volume":"7","author":"K Misselbeck","year":"2017","unstructured":"Misselbeck, K. et al. A hybrid stochastic model of folate-mediated one-carbon metabolism: Effect of the common C677T MTHFR variant on de novo thymidylate biosynthesis. Sci. Reports 7, 797, https:\/\/doi.org\/10.1038\/s41598-017-00854-w (2017).","journal-title":"Sci. Reports"},{"key":"65590_CR6","doi-asserted-by":"publisher","first-page":"117693511879975","DOI":"10.1177\/1176935118799754","volume":"17","author":"AK Alameddine","year":"2018","unstructured":"Alameddine, A. K., Conlin, F. & Binnall, B. An Introduction to the Mathematical Modeling in the Study of Cancer Systems Biology. Cancer informatics 17, 1176935118799754, https:\/\/doi.org\/10.1177\/1176935118799754 (2018).","journal-title":"Cancer informatics"},{"key":"65590_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0190627","volume":"13","author":"C Uluseker","year":"2018","unstructured":"Uluseker, C. et al. A closed-loop multi-level model of glucose homeostasis. PLoS One 13, 1\u201323, https:\/\/doi.org\/10.1371\/journal.pone.0190627 (2018).","journal-title":"PLoS One"},{"key":"65590_CR8","doi-asserted-by":"publisher","first-page":"4322","DOI":"10.1038\/s41598-019-40230-4","volume":"9","author":"K Misselbeck","year":"2019","unstructured":"Misselbeck, K., Marchetti, L., Priami, C., Stover, P. J. & Field, M. S. The 5-formyltetrahydrofolate futile cycle reduces pathway stochasticity in an extended hybrid-stochastic model of folate-mediated one-carbon metabolism. Sci. Reports 9, 4322, https:\/\/doi.org\/10.1038\/s41598-019-40230-4 (2019).","journal-title":"Sci. Reports"},{"key":"65590_CR9","doi-asserted-by":"publisher","first-page":"36029","DOI":"10.1038\/srep36029","volume":"6","author":"L Marchetti","year":"2016","unstructured":"Marchetti, L. et al. A Novel Insulin\/Glucose Model after a Mixed-Meal Test in Patients with Type 1 Diabetes on Insulin Pump Therapy. Sci. Reports 6, 36029, https:\/\/doi.org\/10.1038\/srep36029 (2016).","journal-title":"Sci. Reports"},{"key":"65590_CR10","doi-asserted-by":"crossref","unstructured":"Marchetti, L., Priami, C. & Thanh, V. H. Simulation Algorithms for Computational Systems Biology, 1 edn. (Springer International Publishing, 2017).","DOI":"10.1007\/978-3-319-63113-4_1"},{"issue":"2","key":"65590_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/bib\/bbz014","volume":"21","author":"Giulia Simoni","year":"2019","unstructured":"Simoni, G., Vo, H. T., Priami, C. & Marchetti, L. A comparison of deterministic and stochastic approaches for sensitivity analysis in computational systems biology. Briefings Bioinformatics, 21(2), 527\u2013540,\u00a0https:\/\/doi.org\/10.1093\/bib\/bbz014 (2019).","journal-title":"Briefings in Bioinformatics"},{"key":"65590_CR12","doi-asserted-by":"publisher","first-page":"e1459","DOI":"10.1002\/wsbm.1459","volume":"11","author":"G Simoni","year":"2019","unstructured":"Simoni, G., Reali, F., Priami, C. & Marchetti, L. Stochastic simulation algorithms for computational systems biology: Exact, approximate, and hybrid methods. Wiley Interdiscip. Rev. Syst. Biol. Medicine 11, e1459, https:\/\/doi.org\/10.1002\/wsbm.1459 (2019).","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Medicine"},{"key":"65590_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fams.2017.00006","volume":"3","author":"F Reali","year":"2017","unstructured":"Reali, F., Priami, C. & Marchetti, L. Optimization Algorithms for Computational Systems Biology. Front. Appl. Math. Stat. 3, 6, https:\/\/doi.org\/10.3389\/fams.2017.00006 (2017).","journal-title":"Front. Appl. Math. Stat."},{"key":"65590_CR14","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1080\/14737140.2018.1527689","volume":"18","author":"AM Jarrett","year":"2018","unstructured":"Jarrett, A. M. et al. Mathematical models of tumor cell proliferation: A review of the literature. Expert. Rev. Anticancer. Ther. 18, 1271\u20131286, https:\/\/doi.org\/10.1080\/14737140.2018.1527689 (2018).","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"65590_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jtbi.2018.03.014","volume":"446","author":"E Piretto","year":"2018","unstructured":"Piretto, E., Delitala, M. & Ferraro, M. Combination therapies and intra-tumoral competition: Insights from mathematical modeling. J. Theor. Biol. 446, 149\u2013159, https:\/\/doi.org\/10.1016\/j.jtbi.2018.03.014 (2018).","journal-title":"J. Theor. Biol."},{"key":"65590_CR16","doi-asserted-by":"publisher","unstructured":"Metzcar, J., Wang, Y., Heiland, R. & Macklin, P. A Review of Cell-Based Computational Modeling in Cancer Biology. JCO Clin. Cancer Informatics 1\u201313, https:\/\/doi.org\/10.1200\/CCI.18.00069 (2019).","DOI":"10.1200\/CCI.18.00069"},{"key":"65590_CR17","unstructured":"Sorger, P. K. et al. Quantitative and systems pharmacology in the postgenomic era: New approaches to discovering drugs and understanding therapeutic mechanisms. QSP White Pap. 1\u201348 (2011)."},{"issue":"9","key":"65590_CR18","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1038\/psp.2013.49","volume":"2","author":"O Demin","year":"2013","unstructured":"Demin, O. et al. Systems pharmacology models can be used to understandcomplex pharmacokinetic-pharmacodynamic behavior: An example using 5-lipoxygenase inhibitors. CPT: Pharmacometrics Syst. Pharmacol. 2, https:\/\/doi.org\/10.1038\/psp.2013.49 (2013).","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"65590_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ddtec.2016.11.001","volume":"21\u201322","author":"K Gadkar","year":"2016","unstructured":"Gadkar, K., Kirouac, D., Parrott, N. & Ramanujan, S. Quantitative systems pharmacology: a promising approach for translational pharmacology. Drug Discov. Today: Technol. 21\u201322, 57\u201365, https:\/\/doi.org\/10.1016\/j.ddtec.2016.11.001 (2016).","journal-title":"Drug Discov. Today: Technol."},{"key":"65590_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/psp4.12056","volume":"5","author":"CM Friedrich","year":"2016","unstructured":"Friedrich, C. M. A model qualification method for mechanistic physiological QSP models to support model-informed drug development. CPT: Pharmacometrics Syst. Pharmacol. 5, 43\u201353, https:\/\/doi.org\/10.1002\/psp4.12056 (2016).","journal-title":"CPT: Pharmacometrics Syst. Pharmacol."},{"key":"65590_CR21","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.ymgme.2017.12.183","volume":"123","author":"C Kaddi","year":"2018","unstructured":"Kaddi, C. et al. Integrated quantitative systems pharmacology (QSP) model of lysosomal diseases provides an innovative computational platform to support research and therapeutic development for the sphingolipidoses. Mol. Genet. Metab. 123, S73\u2013S74, https:\/\/doi.org\/10.1016\/j.ymgme.2017.12.183 (2018).","journal-title":"Mol. Genet. Metab."},{"key":"65590_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/psp4.12463","volume":"0","author":"EL Bradshaw","year":"2019","unstructured":"Bradshaw, E. L. et al. Applications of Quantitative Systems Pharmacology in Model-Informed Drug Discovery: Perspective on Impact and Opportunities. CPT: Pharmacometrics & Syst. Pharmacol. 0, 1\u201315, https:\/\/doi.org\/10.1002\/psp4.12463 (2019).","journal-title":"CPT: Pharmacometrics & Syst. Pharmacol."},{"key":"65590_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/pr3020235","volume":"3","author":"C Byrne-Hoffman","year":"2015","unstructured":"Byrne-Hoffman, C. & Klinke, D. J. II. A Quantitative Systems Pharmacology Perspective on Cancer Immunology. Process. 3, 235\u2013256, https:\/\/doi.org\/10.3390\/pr3020235 (2015).","journal-title":"Process."},{"key":"65590_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-016-0623-5","volume":"14","author":"S Farkona","year":"2016","unstructured":"Farkona, S., Diamandis, E. P. & Blasutig, I. M. Cancer immunotherapy: The beginning of the end of cancer? BMC Medicine 14, 1\u201318, https:\/\/doi.org\/10.1186\/s12916-016-0623-5 (2016).","journal-title":"BMC Medicine"},{"key":"65590_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immun. 39, 1\u201310, https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012 (2013).","journal-title":"Immun."},{"key":"65590_CR26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nat. 480, 480, https:\/\/doi.org\/10.1038\/nature10673 (2011).","journal-title":"Nat."},{"key":"65590_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/01.cji.0000155049.26787.45","volume":"28","author":"PA Antony","year":"2005","unstructured":"Antony, P. A. & Restifo, N. P. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J. immunotherapy (Hagerstown, Md.: 1997) 28, 120\u2013128, https:\/\/doi.org\/10.1097\/01.cji.0000155049.26787.45 (2005).","journal-title":"J. immunotherapy (Hagerstown, Md.: 1997)"},{"issue":"23","key":"65590_CR28","doi-asserted-by":"publisher","first-page":"6947","DOI":"10.1158\/1078-0432.CCR-07-0842","volume":"13","author":"Y. Kiniwa","year":"2007","unstructured":"Kiniwa, Y. et al. CD8+ Foxp3+ Regulatory T Cells Mediate Immunosuppression in Prostate Cancer, https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0842 (2007).","journal-title":"Clinical Cancer Research"},{"key":"65590_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1600-065X.2008.00602.x","volume":"222","author":"I Marigo","year":"2008","unstructured":"Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P. & Bronte, V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222, 162\u2013179, https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00602.x (2008).","journal-title":"Immunol. Rev."},{"key":"65590_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162, https:\/\/doi.org\/10.1038\/nri2506 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"65590_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-15-0224","volume":"6","author":"G Wang","year":"2016","unstructured":"Wang, G. et al. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. Cancer discovery 6, 80\u201395, https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0224 (2016).","journal-title":"Cancer discovery"},{"key":"65590_CR32","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-12-1362","volume":"18","author":"DS Chen","year":"2012","unstructured":"Chen, D. S., Irving, B. A. & Hodi, F. S. Molecular Pathways: Next-Generation Immunotherapy\u2013Inhibiting Programmed Death-Ligand 1 and Programmed Death-1. Clin. Cancer Res. 18, 6580\u20136587, https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1362 (2012).","journal-title":"Clin. Cancer Res."},{"key":"65590_CR33","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1177\/1557988318798279","volume":"12","author":"HE Taitt","year":"2018","unstructured":"Taitt, H. E. Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location. Am. J. Men\u2019s Heal. 12, 1807\u20131823, https:\/\/doi.org\/10.1177\/1557988318798279 (2018).","journal-title":"Am. J. Men\u2019s Heal."},{"key":"65590_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA: A Cancer J. for Clin. 69, 7\u201334, https:\/\/doi.org\/10.3322\/caac.21551 (2019).","journal-title":"CA: A Cancer J. for Clin."},{"issue":"5","key":"65590_CR35","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3322\/caac.21565","volume":"69","author":"Kimberly D. Miller","year":"2019","unstructured":"Miller, K. D. et al. Cancer treatment and survivorship statistics, 2019. CA: A Cancer J. for Clin., https:\/\/doi.org\/10.3322\/caac.21565 (2019).","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"65590_CR36","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","volume":"375","author":"FC Hamdy","year":"2016","unstructured":"Hamdy, F. C. et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. New Engl. J. Medicine 375, 1415\u20131424, https:\/\/doi.org\/10.1056\/NEJMoa1606220 (2016).","journal-title":"New Engl. J. Medicine"},{"key":"65590_CR37","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/00005392-200202000-00018","volume":"167","author":"G Hull","year":"2002","unstructured":"Hull, G. et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. The J. Urol. 167, 528\u2013534, https:\/\/doi.org\/10.1097\/00005392-200202000-00018 (2002).","journal-title":"The J. Urol."},{"issue":"3","key":"65590_CR38","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/01.ju.0000134888.22332.bb","volume":"172","author":"KIMBERLY A. ROEHL","year":"2004","unstructured":"Roehl, K. A., Han, M., Ramos, C. G., Antenor, J. & Catalona, W. J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J. Urol. 172, 910\u2013914, https:\/\/doi.org\/10.1097\/01.ju.0000134888.22332.bb (2004).","journal-title":"Journal of Urology"},{"key":"65590_CR39","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/jnci\/djj190","volume":"98","author":"AJ Stephenson","year":"2006","unstructured":"Stephenson, A. J. et al. Preoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical Prostatectomy. JNCI: J. Natl. Cancer Inst. 98, 715\u2013717, https:\/\/doi.org\/10.1093\/jnci\/djj190 (2006).","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"6","key":"65590_CR40","doi-asserted-by":"publisher","first-page":"a030635","DOI":"10.1101\/cshperspect.a030635","volume":"8","author":"Semini Sumanasuriya","year":"2017","unstructured":"Sumanasuriya, S. & De Bono, J. Treatment of Advanced Prostate Cancer - A Review of Current Therapies and Future Promise. Cold Spring Harb. Perspectives Medicine, https:\/\/doi.org\/10.1101\/cshperspect.a030635 (2017).","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"65590_CR41","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701, https:\/\/doi.org\/10.1038\/nrc4016 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"65590_CR42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/35094009","volume":"1","author":"BJ Feldman","year":"2001","unstructured":"Feldman, B. J. & Feldman, D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34\u201345, https:\/\/doi.org\/10.1038\/35094009 (2001).","journal-title":"Nat. Rev. Cancer"},{"key":"65590_CR43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.33590\/emjurol\/10313570","volume":"7","author":"I Silvestri","year":"2019","unstructured":"Silvestri, I., Tortorella, E., Giantulli, S., Scarpa, S. & Sciarra, A. Immunotherapy in prostate cancer: recent advances and future directions. EMJ Urol. 7, 51\u201361 (2019).","journal-title":"EMJ Urol."},{"issue":"5","key":"65590_CR44","doi-asserted-by":"publisher","first-page":"a030627","DOI":"10.1101\/cshperspect.a030627","volume":"9","author":"Nicholas J. Venturini","year":"2018","unstructured":"Venturini, N. J. & Drake, C. G. Immunotherapy for Prostate Cancer. Cold Spring Harb. Perspectives Medicine 9, https:\/\/doi.org\/10.1101\/cshperspect.a030627 (2019).","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"65590_CR45","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fimmu.2019.00603","volume":"10","author":"N Vitkin","year":"2019","unstructured":"Vitkin, N., Nersesian, S., Siemens, D. R. & Koti, M. The Tumor Immune Contexture of Prostate Cancer. Front. Immunol. 10, 603, https:\/\/doi.org\/10.3389\/fimmu.2019.00603 (2019).","journal-title":"Front. Immunol."},{"key":"65590_CR46","doi-asserted-by":"publisher","first-page":"21599","DOI":"10.1038\/srep21599","volume":"6","author":"H Peng","year":"2016","unstructured":"Peng, H. et al. Prediction of treatment efficacy for prostate cancer using a mathematical model. Sci. Reports 6, 21599, https:\/\/doi.org\/10.1038\/srep21599 (2016).","journal-title":"Sci. Reports"},{"key":"65590_CR47","doi-asserted-by":"publisher","first-page":"3473 LP","DOI":"10.1158\/0008-5472.CAN-09-2490","volume":"70","author":"EJ Akins","year":"2010","unstructured":"Akins, E. J. et al. In situ Vaccination Combined with Androgen Ablation and Regulatory T-Cell Depletion Reduces Castration-Resistant Tumor Burden in Prostate-Specific Pten Knockout Mice. Cancer Res. 70, 3473 LP\u20133482, https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2490 (2010).","journal-title":"Cancer Res."},{"key":"65590_CR48","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1158\/0008-5472.CAN-11-2499","volume":"72","author":"S Tang","year":"2012","unstructured":"Tang, S., Moore, M. L., Grayson, J. M. & Dubey, P. Increased CD8+ T-cell Function following Castration and Immunization Is Countered by Parallel Expansion of Regulatory T Cells. Cancer Res. 72, 1975\u20131985, https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-2499 (2012).","journal-title":"Cancer Res."},{"key":"65590_CR49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.canlet.2017.03.035","volume":"398","author":"S-J Lin","year":"2017","unstructured":"Lin, S.-J. et al. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7). Cancer Lett. 398, 62\u201369, https:\/\/doi.org\/10.1016\/j.canlet.2017.03.035 (2017).","journal-title":"Cancer Lett."},{"key":"65590_CR50","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1128\/MCB.00090-14","volume":"34","author":"AJ Garcia","year":"2014","unstructured":"Garcia, A. J. et al. Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression. Mol. Cell. Biol. 34, 2017\u20132028, https:\/\/doi.org\/10.1128\/MCB.00090-14 (2014).","journal-title":"Mol. Cell. Biol."},{"key":"65590_CR51","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nature21676","volume":"543","author":"X Lu","year":"2017","unstructured":"Lu, X. et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nat. 543, 728, https:\/\/doi.org\/10.1038\/nature21676 (2017).","journal-title":"Nat."},{"issue":"9","key":"65590_CR52","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1158\/0008-5472.CAN-17-1201","volume":"78","author":"Elysia C. Saputra","year":"2018","unstructured":"Saputra, E. C., Huang, L., Chen, Y. & Tucker-Kellogg, L. Combination Therapy and the Evolution of Resistance: The Theoretical Merits of Synergism and Antagonism in Cancer. Cancer Res., https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1201 (2018).","journal-title":"Cancer Research"},{"key":"65590_CR53","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1093\/bioinformatics\/btr431","volume":"27","author":"O Chi\u015f","year":"2011","unstructured":"Chi\u015f, O., Banga, J. R. & Balsa-Canto, E. GenSSI: a software toolbox for structural identifiability analysis of biological models. Bioinforma. (Oxford, England) 27, 2610\u20132611, https:\/\/doi.org\/10.1093\/bioinformatics\/btr431 (2011).","journal-title":"Bioinforma. (Oxford, England)"},{"key":"65590_CR54","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264, https:\/\/doi.org\/10.1038\/nrc3239 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"65590_CR55","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.clim.2004.04.003","volume":"112","author":"P Trzonkowski","year":"2004","unstructured":"Trzonkowski, P., Szmit, E., My\u015bliwska, J., Dobyszuk, A. & My\u015bliwski, A. CD4 +CD25 + T regulatory cells inhibit cytotoxic activity of T CD8 + and NK lymphocytes in the direct cell-to-cell interaction. Clin. Immunol. 112, 258\u2013267, https:\/\/doi.org\/10.1016\/j.clim.2004.04.003 (2004).","journal-title":"Clin. Immunol."},{"key":"65590_CR56","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3934\/dcdsb.2013.18.915","volume":"18","author":"L de Pillis","year":"2013","unstructured":"de Pillis, L., Caldwell, T., Sarapata, E. & Williams, H. Mathematical modeling of regulatory T cell effects on renal cell carcinoma treatment. Discret. Continuous Dyn. Syst. - Ser. B 18, 915\u2013943, https:\/\/doi.org\/10.3934\/dcdsb.2013.18.915 (2013).","journal-title":"Discret. Continuous Dyn. Syst. - Ser. B"},{"key":"65590_CR57","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/intimm\/dxp095","volume":"21","author":"S Sakaguchi","year":"2009","unstructured":"Sakaguchi, S., Wing, K., Onishi, Y., Prieto-Martin, P. & Yamaguchi, T. Regulatory T cells: how do they suppress immune responses? Int. Immunol. 21, 1105\u20131111, https:\/\/doi.org\/10.1093\/intimm\/dxp095 (2009).","journal-title":"Int. Immunol."},{"key":"65590_CR58","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1158\/0008-5472.CAN-12-4414","volume":"73","author":"N Mitsiades","year":"2013","unstructured":"Mitsiades, N. A Road Map to Comprehensive Androgen Receptor Axis Targeting for Castration-Resistant Prostate Cancer. Cancer Res. 73, 4599\u20134605, https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-4414 (2013).","journal-title":"Cancer Res."},{"key":"65590_CR59","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3934\/dcdsb.2017050","volume":"22","author":"EM Rutter","year":"2017","unstructured":"Rutter, E. M. & Kuang, Y. Global dynamics of a model of joint hormone treatment with dendritic cell vaccine for prostate cancer. Discret. Continuous Dyn. Syst. - Ser. B 22, 1001\u20131021, https:\/\/doi.org\/10.3934\/dcdsb.2017050 (2017).","journal-title":"Discret. Continuous Dyn. Syst. - Ser. B"},{"key":"65590_CR60","unstructured":"The Jackson Laboratory. Body Weight Information For DBA\/2J (000671), JAX Mice Strain - DBA\/2J, https:\/\/www.jax.org\/jax-mice-and-services\/strain-data-sheet-pages\/body-weight-chart-000671 (2019)."},{"key":"65590_CR61","unstructured":"The Jackson Laboratory. Body Weight Information For C57BL\/6J (000664), JAX Mice Strain - C57BL\/6J, https:\/\/www.jax.org\/jax-mice-and-services\/strain-data-sheet-pages\/body-weight-chart-000664 (2019)."},{"key":"65590_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/421702","volume":"2012","author":"Laure Farnault","year":"2012","unstructured":"Farnault, L., Sanchez, C., Baier, C., Le Treut, T. & Costello, R. T. Hematological Malignancies Escape from NK Cell Innate Immune Surveillance: Mechanisms and Therapeutic Implications. Clin. Dev. Immunol. 2012, https:\/\/doi.org\/10.1155\/2012\/421702 (2012).","journal-title":"Clinical and Developmental Immunology"},{"key":"65590_CR63","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1158\/0008-5472.CAN-15-1965","volume":"76","author":"C Pasero","year":"2016","unstructured":"Pasero, C. et al. Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity. Cancer Res. 76, 2153\u20132165, https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1965 (2016).","journal-title":"Cancer Res."},{"key":"65590_CR64","doi-asserted-by":"publisher","first-page":"101578","DOI":"10.1016\/j.canep.2019.101578","volume":"62","author":"AC Vidal","year":"2019","unstructured":"Vidal, A. C. et al. Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy. Cancer Epidemiol. 62, 101578, https:\/\/doi.org\/10.1016\/j.canep.2019.101578 (2019).","journal-title":"Cancer Epidemiol."},{"key":"65590_CR65","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/000325465","volume":"3","author":"A Stojanovic","year":"2011","unstructured":"Stojanovic, A. & Cerwenka, A. Natural Killer Cells and Solid Tumors. J. Innate Immun. 3, 355\u2013364, https:\/\/doi.org\/10.1159\/000325465 (2011).","journal-title":"J. Innate Immun."},{"key":"65590_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jtbi.2018.01.006","volume":"442","author":"SP Shariatpanahi","year":"2018","unstructured":"Shariatpanahi, S. P., Shariatpanahi, S. P., Madjidzadeh, K., Hassan, M. & Abedi-Valugerdi, M. Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic targeting strategies. J. Theor. Biol. 442, 1\u201310, https:\/\/doi.org\/10.1016\/j.jtbi.2018.01.006 (2018).","journal-title":"J. Theor. Biol."},{"key":"65590_CR67","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1177\/1535370216660212","volume":"241","author":"KM Doersch","year":"2016","unstructured":"Doersch, K. M., Moses, K. A. & Zimmer, W. E. Synergistic immunologic targets for the treatment of prostate cancer. Exp. Biol. Medicine 241, 1900\u20131910, https:\/\/doi.org\/10.1177\/1535370216660212 (2016).","journal-title":"Exp. Biol. Medicine"},{"key":"65590_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mbs.2017.07.006","volume":"292","author":"M Qomlaqi","year":"2017","unstructured":"Qomlaqi, M., Bahrami, F., Ajami, M. & Hajati, J. An extended mathematical model of tumor growth and its interaction with the immune system, to be used for developing an optimized immunotherapy treatment protocol. Math. Biosci. 292, 1\u20139, https:\/\/doi.org\/10.1016\/j.mbs.2017.07.006 (2017).","journal-title":"Math. Biosci."},{"key":"65590_CR69","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/17486700802216301","volume":"10","author":"L de Pillis","year":"2009","unstructured":"de Pillis, L. et al. Mathematical model creation for cancer chemo-immunotherapy. Comput. Math. Methods Medicine 10, 165\u2013184, https:\/\/doi.org\/10.1080\/17486700802216301 (2009).","journal-title":"Comput. Math. Methods Medicine"},{"key":"65590_CR70","unstructured":"Usman, A. & Cunningham, C. Application of the Mathematical Model of Tumor- Immune Interactions for IL-2 Adoptive Immunotherapy to Studies on Patients with Metastatic Melanoma or Renal Cell Cancer. Rose-Hulman Undergrad. Math. J. 6 (2005)."},{"key":"65590_CR71","unstructured":"US Food and Drug Administration\/Center for Drug Evaluation and Research. Application number 203756Orig1s000 Pharmacology\/Toxicology NDA Review And Evaluation (2012)."},{"key":"65590_CR72","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/978-1-59259-734-5_29","volume-title":"Handbook of Anticancer Pharmacokinetics and Pharmacodynamics","author":"Victor Ghetie","year":"2004","unstructured":"Ghetie, V. G., Sally Ward, E. & Vitetta, E. The Pharmacokinetics of Antibodies and Immunotoxins in Mice and Humans. In Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, chap. 29, 298\u2013475, https:\/\/doi.org\/10.1007\/978-1-59259-734-5_29 (Humana Press, Totowa, NJ, 2004)."},{"key":"65590_CR73","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman, J. T. & Meibohm, B. Pharmacokinetics of Monoclonal Antibodies. CPT: pharmacometrics & systems pharmacology 6, 576\u2013588, https:\/\/doi.org\/10.1002\/psp4.12224 (2017).","journal-title":"CPT: pharmacometrics & systems pharmacology"},{"key":"65590_CR74","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","volume":"26","author":"CI BLISS","year":"1939","unstructured":"BLISS, C. I. The Toxicity Of Poisons Applied Jointly1. Annals Appl. Biol. 26, 585\u2013615, https:\/\/doi.org\/10.1111\/j.1744-7348.1939.tb06990.x (1939).","journal-title":"Annals Appl. Biol."},{"key":"65590_CR75","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1182\/blood.V93.2.728","volume":"93","author":"DB Fearnley","year":"1999","unstructured":"Fearnley, D. B., Whyte, L. F., Carnoutsos, S. A., Cook, A. H. & Hart, D. N. J. Monitoring Human Blood Dendritic Cell Numbers in Normal Individuals and in Stem Cell Transplantation. Blood 93, 728\u2013736 (1999).","journal-title":"Blood"},{"key":"65590_CR76","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.3390\/app10082721","volume":"10","author":"T Phan","year":"2020","unstructured":"Phan, T. et al. Review: Mathematical modeling of prostate cancer and clinical application. Appl. Sci. 10, 2721, https:\/\/doi.org\/10.3390\/app10082721 (2020).","journal-title":"Appl. Sci."},{"issue":"1","key":"65590_CR77","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3934\/dcdsb.2004.4.187","volume":"4","author":"T.L. Jackson","year":"2003","unstructured":"Jackson, T. L. A mathematical model of prostate tumor growth and androgen-independent relapse. Discret. & Continuous Dyn. Syst. - B 4, https:\/\/doi.org\/10.3934\/dcdsb.2004.4.187 (2004).","journal-title":"Discrete and Continuous Dynamical Systems - Series B"},{"key":"65590_CR78","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00332-008-9031-0","volume":"18","author":"AM Ideta","year":"2008","unstructured":"Ideta, A. M., Tanaka, G., Takeuchi, T. & Aihara, K. A Mathematical Model of Intermittent Androgen Suppression for Prostate Cancer. J. Nonlinear Sci. 18, 593, https:\/\/doi.org\/10.1007\/s00332-008-9031-0 (2008).","journal-title":"J. Nonlinear Sci."},{"issue":"12","key":"65590_CR79","doi-asserted-by":"publisher","first-page":"e15482","DOI":"10.1371\/journal.pone.0015482","volume":"5","author":"Natalie Kronik","year":"2010","unstructured":"Kronik, N. et al. Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models. PLoS One 5, https:\/\/doi.org\/10.1371\/journal.pone.0015482 (2010).","journal-title":"PLoS ONE"},{"key":"65590_CR80","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jtbi.2010.02.027","volume":"264","author":"Y Hirata","year":"2010","unstructured":"Hirata, Y., Bruchovsky, N. & Aihara, K. Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer. J. Theor. Biol. 264, 517\u2013527, https:\/\/doi.org\/10.1016\/j.jtbi.2010.02.027 (2010).","journal-title":"J. Theor. Biol."},{"issue":"11","key":"65590_CR81","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/app6110352","volume":"6","author":"Javier Baez","year":"2016","unstructured":"Baez, J. & Kuang, Y. Mathematical Models of Androgen Resistance in Prostate Cancer Patients under Intermittent Androgen Suppression Therapy. Appl. Sci. 6, https:\/\/doi.org\/10.3390\/app6110352 (2016).","journal-title":"Applied Sciences"},{"key":"65590_CR82","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nature13638","volume":"515","author":"D Di Mitri","year":"2014","unstructured":"Di Mitri, D. et al. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nat. 515, 134, https:\/\/doi.org\/10.1038\/nature13638 (2014).","journal-title":"Nat."},{"key":"65590_CR83","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/jco.2015.33.7_suppl.222","volume":"33","author":"KA Autio","year":"2015","unstructured":"Autio, K. A. et al. Presence of myeloid-derived suppressor cells (MDSC) in patients with metastatic castration-sensitive and castration-resistant prostate cancer. J. Clin. Oncol. 33, 222, https:\/\/doi.org\/10.1200\/jco.2015.33.7_suppl.222 (2015).","journal-title":"J. Clin. Oncol."},{"key":"65590_CR84","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3389\/fimmu.2018.00398","volume":"9","author":"V Fleming","year":"2018","unstructured":"Fleming, V. et al. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. Front. Immunol. 9, 398, https:\/\/doi.org\/10.3389\/fimmu.2018.00398 (2018).","journal-title":"Front. Immunol."},{"key":"65590_CR85","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","volume":"559","author":"A Calcinotto","year":"2018","unstructured":"Calcinotto, A. et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nat. 559, 363\u2013369, https:\/\/doi.org\/10.1038\/s41586-018-0266-0 (2018).","journal-title":"Nat."},{"key":"65590_CR86","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.tips.2018.10.008","volume":"40","author":"RJ Tesi","year":"2019","unstructured":"Tesi, R. J. MDSC; the Most Important Cell You Have Never Heard Of. Trends Pharmacol. Sci. 40, 4\u20137, https:\/\/doi.org\/10.1016\/j.tips.2018.10.008 (2019).","journal-title":"Trends Pharmacol. Sci."},{"key":"65590_CR87","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.intimp.2018.08.007","volume":"63","author":"RP Tobin","year":"2018","unstructured":"Tobin, R. P. et al. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int. Immunopharmacol. 63, 282\u2013291, https:\/\/doi.org\/10.1016\/j.intimp.2018.08.007 (2018).","journal-title":"Int. Immunopharmacol."},{"key":"65590_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ebiom.2019.01.018","volume":"39","author":"Editorial Overview","year":"2019","unstructured":"Editorial Overview. Natural killer cells for cancer immunotherapy: a new CAR is catching up. EBioMedicine 39, 1\u20132, https:\/\/doi.org\/10.1016\/j.ebiom.2019.01.018 (2019).","journal-title":"EBioMedicine"},{"issue":"1","key":"65590_CR89","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/cancers11010055","volume":"11","author":"Alexander Barrow","year":"2019","unstructured":"Barrow, A. D. & Colonna, M. Exploiting NK Cell Surveillance Pathways for Cancer Therapy. Cancers 11, https:\/\/doi.org\/10.3390\/cancers11010055 (2019).","journal-title":"Cancers"},{"issue":"11","key":"65590_CR90","doi-asserted-by":"publisher","first-page":"19352","DOI":"10.1002\/jcp.28657","volume":"234","author":"Behnaz Valipour","year":"2019","unstructured":"Valipour, B. et al. NK cells: An attractive candidate for cancer therapy. J. Cell. Physiol., https:\/\/doi.org\/10.1002\/jcp.28657 (2019).","journal-title":"Journal of Cellular Physiology"},{"key":"65590_CR91","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","volume":"25","author":"K Rezvani","year":"2017","unstructured":"Rezvani, K., Rouce, R., Liu, E. & Shpall, E. Engineering Natural Killer Cells for Cancer Immunotherapy. Mol. Ther. 25, 1769\u20131781, https:\/\/doi.org\/10.1016\/j.ymthe.2017.06.012 (2017).","journal-title":"Mol. Ther."},{"key":"65590_CR92","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1158\/1078-0432.CCR-06-2318","volume":"13","author":"EJ Small","year":"2007","unstructured":"Small, E. J. et al. A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer. Clin. Cancer Res. 13, 1810\u20131815, https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2318 (2007).","journal-title":"Clin. Cancer Res."},{"key":"65590_CR93","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.pharmthera.2018.09.008","volume":"194","author":"A Constantinidou","year":"2019","unstructured":"Constantinidou, A., Alifieris, C. & Trafalis, D. T. Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. Pharmacol. & Ther. 194, 84\u2013106, https:\/\/doi.org\/10.1016\/j.pharmthera.2018.09.008 (2019).","journal-title":"Pharmacol. & Ther."},{"key":"65590_CR94","doi-asserted-by":"publisher","first-page":"293","DOI":"10.4081\/oncol.2016.293","volume":"10","author":"A Modena","year":"2016","unstructured":"Modena, A. et al. Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? Oncol. reviews 10, 293, https:\/\/doi.org\/10.4081\/oncol.2016.293 (2016).","journal-title":"Oncol. reviews"},{"key":"65590_CR95","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Sci. 359, 1350\u20131355, https:\/\/doi.org\/10.1126\/science.aar4060 (2018).","journal-title":"Sci."},{"key":"65590_CR96","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.urolonc.2017.09.024","volume":"35","author":"JM Redman","year":"2017","unstructured":"Redman, J. M., Gulley, J. L. & Madan, R. A. Combining immunotherapies for the treatment of prostate cancer. Urol. Oncol. Semin. Orig. Investig. 35, 694\u2013700, https:\/\/doi.org\/10.1016\/j.urolonc.2017.09.024 (2017).","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"issue":"6","key":"65590_CR97","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/MOU.0000000000000433","volume":"27","author":"Andrew L. Laccetti","year":"2017","unstructured":"Laccetti, A. L. & Subudhi, S. K. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg? Curr. Opin. Urol. 27, https:\/\/doi.org\/10.1097\/MOU.0000000000000433 (2017).","journal-title":"Current Opinion in Urology"},{"issue":"22","key":"65590_CR98","doi-asserted-by":"publisher","first-page":"6764","DOI":"10.1158\/1078-0432.CCR-17-0019","volume":"23","author":"Marijo Bilusic","year":"2017","unstructured":"Bilusic, M., Madan, R. A. & Gulley, J. L. Immunotherapy of Prostate Cancer: Facts and Hopes. Clin. Cancer Res., https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0019 (2017).","journal-title":"Clinical Cancer Research"},{"key":"65590_CR99","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1200\/JCO.2018.36.15_suppl.5047","volume":"36","author":"JN Graff","year":"2018","unstructured":"Graff, J. N. et al. Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): Extended follow up. J. Clin. Oncol 36, 5047, https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.5047 (2018).","journal-title":"J. Clin. Oncol"},{"key":"65590_CR100","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/ITT.S122497","volume":"6","author":"M Scholz","year":"2017","unstructured":"Scholz, M. et al. Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer. ImmunoTargets Ther. 6, 11\u201316, https:\/\/doi.org\/10.2147\/ITT.S122497 (2017).","journal-title":"ImmunoTargets Ther."},{"key":"65590_CR101","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jtbi.2011.10.027","volume":"294","author":"M Robertson-Tessi","year":"2012","unstructured":"Robertson-Tessi, M., El-Kareh, A. & Goriely, A. A mathematical model of tumor\u2013immune interactions. J. Theor. Biol. 294, 56\u201373, https:\/\/doi.org\/10.1016\/j.jtbi.2011.10.027 (2012).","journal-title":"J. Theor. Biol."},{"key":"65590_CR102","first-page":"473","volume":"4","author":"J Wright","year":"1993","unstructured":"Wright, J., Turley, E. & Greenberg, A. Transforming growth factor beta and fibroblast growth factor as promoters of tumor progression to malignancy. Critical reviews oncogenesis 4, 473\u201392 (1993).","journal-title":"Critical reviews oncogenesis"},{"key":"65590_CR103","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1210\/en.2012-2074","volume":"154","author":"BT Vo","year":"2013","unstructured":"Vo, B. T. et al. TGF-b Effects on Prostate Cancer Cell Migration and Invasion Are Mediated by PGE2 through Activation of PI3K\/AKT\/mTOR Pathway. Endocrinol 154, 1768\u20131779, https:\/\/doi.org\/10.1210\/en.2012-2074 (2013).","journal-title":"Endocrinol"},{"key":"65590_CR104","doi-asserted-by":"publisher","first-page":"7111","DOI":"10.1158\/0008-5472.CAN-08-3957","volume":"69","author":"D Basanta","year":"2009","unstructured":"Basanta, D. et al. The role of transforming growth factor-beta-mediated tumor-stroma interactions in prostate cancer progression: an integrative approach. Cancer research 69, 7111\u20137120, https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3957 (2009).","journal-title":"Cancer research"},{"key":"65590_CR105","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen, A. et al. Cytokine release syndrome. J. for ImmunoTherapy Cancer 6, 56, https:\/\/doi.org\/10.1186\/s40425-018-0343-9 (2018).","journal-title":"J. for ImmunoTherapy Cancer"},{"key":"65590_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0178479","volume":"12","author":"X Lai","year":"2017","unstructured":"Lai, X. & Friedman, A. Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model. PLoS One 12, 1\u201324, https:\/\/doi.org\/10.1371\/journal.pone.0178479 (2017).","journal-title":"PLoS One"},{"key":"65590_CR107","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2164\/jandrol.111.013987","volume":"33","author":"PJ Hensley","year":"2012","unstructured":"Hensley, P. J. & Kyprianou, N. Modeling Prostate Cancer in Mice: Limitations and Opportunities. J. Androl. 33, 133\u2013144, https:\/\/doi.org\/10.2164\/jandrol.111.013987 (2012).","journal-title":"J. Androl."},{"key":"65590_CR108","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3389\/fimmu.2015.00264","volume":"6","author":"A Domogala","year":"2015","unstructured":"Domogala, A., Madrigal, J. A. & Saudemont, A. Natural Killer Cell Immunotherapy: From Bench to Bedside. Front. Immunol. 6, 264, https:\/\/doi.org\/10.3389\/fimmu.2015.00264 (2015).","journal-title":"Front. Immunol."},{"key":"65590_CR109","doi-asserted-by":"publisher","first-page":"945","DOI":"10.13031\/2013.23159","volume":"50","author":"H Wei","year":"2007","unstructured":"Wei, H., A. Nearing, M. & Stone, J. J. A Comprehensive Sensitivity Analysis Framework for Model Evaluation and Improvement Using a Case Study of the Rangeland Hydrology and Erosion Model. Transactions ASABE 50, 945\u2013953, https:\/\/doi.org\/10.13031\/2013.23159 (2007).","journal-title":"Transactions ASABE"},{"key":"65590_CR110","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1049\/iet-syb.2011.0015","volume":"5","author":"Z Zi","year":"2011","unstructured":"Zi, Z. Sensitivity analysis approaches applied to systems biology models. IET Syst. Biol. 5, 336\u2013346(10) (2011).","journal-title":"IET Syst. Biol."},{"key":"65590_CR111","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/00224065.1981.11978748","volume":"13","author":"RL Iman","year":"1981","unstructured":"Iman, R. L., Helton, J. C. & Campbell, J. E. An approach to sensitivity analysis of computer models: Part I \u2013 introduction, input variable selection and preliminary variable assessment. J. Qual. Technol. 13, 174\u2013183, https:\/\/doi.org\/10.1080\/00224065.1981.11978748 (1981).","journal-title":"J. Qual. Technol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65590-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65590-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65590-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T22:14:33Z","timestamp":1696198473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-65590-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["65590"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-65590-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"assertion":[{"value":"13 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9063"}}